Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel - PubMed
3 months ago
- #biomarkers
- #survivorship
- #prostate cancer
- Expansion of treatment options for prostate cancer has improved survival outcomes but raised questions about optimal treatment levels based on individual prognosis and quality of life.
- Multidisciplinary experts discussed current controversies in prostate cancer care, focusing on biomarker-guided assessment, imaging, and systemic therapy.
- Key topics included genomic biomarkers, AI-guided tools for high-risk localized disease, management of biochemical recurrence, and treatment escalation for metastatic hormone-sensitive PC.
- Radiopharmaceutical therapy for metastatic castration-resistant PC and the role of imaging in extraprostatic disease were highlighted.
- Lifestyle interventions to optimize survivorship and the need for ongoing research to optimize risk-based treatment and therapy sequencing were emphasized.
- Unresolved questions remain about biomarker-based risk stratification, PSMA-PET imaging, and balancing treatment-related toxicity with PC-related death risks.